Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIV4 vs IIV4 in Children 3-8 Years
NCT05513391Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, triple-blind trial of influenza B virus (B/Massachusetts/2/2012) recombinant hemagglutinin in influenza (2 cohorts), sponsored by Sanofi. Primary endpoints: Geometric Mean Titers of Influenza Vaccine Antibodies at Day 57 and Percentage of Participants With Seroconversion Against Antigens at Day 57. Started Nov 2022; status: terminated.
02
Drugs
influenza B virus (B/Massachusetts/2/2012) recombinant hemagglutinin
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05513391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513391.